Circulating Malondialdehyde-Modified LDL-Related Variables and Coronary Artery Stenosis in Asymptomatic Patients with Type 2 Diabetes
Table 1
Characteristics of study participants.
Coronary artery stenosis
value
(−)
(+)
= 19
= 17
Age (years)
57 ± 15
62 ± 7
0.094
Male/female
9/10
12/5
0.192
BMI (kg/m2)
26.4 ± 5.7
27.2 ± 4.8
0.642
Duration of diabetes (years)
3.0 (1.0–11.0)
6.0 (12.0–20.5)
0.007
Hypertension, (%)
12 (63)
14 (82)
0.274
Systolic blood pressure (mmHg)
123 ± 19
138 ± 15
0.015
Diastolic blood pressure (mmHg)
73 ± 13
77 ± 10
0.448
Smoking, (%)
10 (53)
8 (47)
1.000
Retinopathy, (%)
3 (16)
12 (71)
0.002
Nephropathy, (%)
6 (32)
11 (65)
0.057
Neuropathy, (%)
12 (63)
14 (83)
0.274
HbA1c (%)
10.1 ± 1.8
9.5 ± 1.3
0.313
Fasting plasma glucose (mmol/L)
8.1 ± 2.4
7.9 ± 2.0
0.856
Total cholesterol (mmol/L)
5.02 ± 0.96
4.58 ± 0.97
0.183
LDL cholesterol (mmol/L)
3.13 ± 0.82
2.76 ± 0.79
0.185
HDL cholesterol (mmol/L)
1.20 ± 0.38
0.98 ± 0.15
0.031
MDA-LDL (U/L)
70 ± 40
93 ± 57
0.161
MDA-LDL/LDL-C (U/mmol)
23.3 ± 12.3
32.9 ± 11.3
0.020
MDA-LDL/HDL-C (U/mmol)
63.8 ± 45.3
100.3 ± 74.4
0.080
(MDA-LDL/LDL-C)/HDL-C (U·L/mmol2)
21.3 ± 13.8
34.9 ± 15.2
0.008
Triglycerides (mmol/L)
1.50 ± 0.60
1.82 ± 0.71
0.148
Medications, (%)
Insulin treatment
8 (42)
3 (18)
0.156
Sulfonylurea
6 (32)
6 (35)
1.000
Glinides
2 (11)
2 (12)
1.000
Metformin
7 (37)
9 (53)
0.503
Thiazolidinedione
0 (0)
2 (12)
0.216
-Glucosidase inhibitor
0 (0)
3 (18)
0.095
Incretin-related therapies
5 (26)
8 (47)
0.299
Statin
8 (42)
7 (41)
1.000
Data are mean ± SD or median (interquartile range). BMI: body mass index; hypertension: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or treatment; MDA-LDL: malondialdehyde-modified LDL; MDA-LDL-C/LDL-C: MDA-LDL-to-LDL cholesterol ratio; MDA-LDL-C/HDL-C: MDA-LDL-to-HDL cholesterol ratio; (MDA-LDL/LDL-C)/HDL-C: (MDA-LDL/LDL-C) to HDL cholesterol ratio.
